Status:
COMPLETED
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
Lead Sponsor:
Guangzhou Institute of Respiratory Disease
Conditions:
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This single-arm, retrospective study aims to evaluate the safety and efficacy of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (...
Detailed Description
This study evaluates the use of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (PH), including both pulmonary arterial hypertensi...
Eligibility Criteria
Inclusion
- Patients diagnosed with severe pulmonary hypertension (PAH or CLD-PH) requiring lung transplantation
- Age 18 years or older
- Able to provide informed consent
Exclusion
- Patients with PH caused by left heart disease
- Patients unable to undergo lung transplantation due to medical conditions
- Patients with a history of severe drug allergies
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2024
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06605326
Start Date
January 1 2015
End Date
September 1 2024
Last Update
September 23 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.